Benzinga's Volume Movers

surged 21.07% to $26.49. The volume of Neurocrine Biosciences shares traded 1407% higher than normal.

, in cooperation with Neurocrine Biosciences, announced positive top-line results from Phase 3 study of investigational medicine elagolix.

shares climbed 11.18% to $13.92. The volume of Halozyme Therapeutics shares traded was 854% higher than normal. MLV & Co reiterated a Buy rating on Halozyme Therapeutics and raised the price target from $12.00 to $15.00.

shares rose 29.23% to $17.55. The volume of PDF Solutions shares traded was 744% higher than normal. PDF Solutions reported the signing of two contracts and related effects on expected revenues.

shares moved up 1.89% to $72.40. The volume of GW Pharmaceuticals traded was 613% higher than normal. GW Pharma and Otsuka reported results in first of three Sativex Phase 3 cancer pain trials.